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CHILDREN'S ADHERENCE TO HAART
ADHERENCE
A review of published work conducted internationally
reveals what has been learnt about paediatric adherence so
far.
WHAT WE 'KNOW' SO FAR - A REVIEW OF THE
UTERATURE
In a study looking at adherence to antiretroviral therapy
and Pneumacystis carinii prophylaxis, in HIV disease in
children, conducted by Eldred et al.' in 1998, 60% of
parents reported;:" 80% adherence over a prior 7-day
period. Adherence was found to be correlated with:
• simple regimens (twice daily) and
• belief in ability to adhere, and
• were uncorrelated to sociodemographics or belief in
efficacy.
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The so-called PENTA 1 trial' conducted by the Paediatric
European Network for Treatment of AIDS studied parents'
attitudes to their HIV-infected children being enrolled imo
a placebo-controlled trial. When asked to describe the
degree of interference with daily life that the
administration of the medication caused, 43% of parents
described it as 'moderate' or 'great: Caregivers' concerns
included forgetting to administer doses of medication,
tasre of medicine, and volume of trial medication. The
findings underline the importance of trying to develop and
evaluate innovative ways of helping families with these
problems.
A more recent article' confirmed adherence as a
determinant of response to HAART in children. One
hundred and ninety-three children were enrolled in the
study, which compared various combinations of d4T, 3TC,
nevirapine, ritonavir and nelfinavir. From this group, 125
completed full data sets of 3-monthly questionnaires.
Seventy per cent of the 125 achieved complete adherence,
while 30% were non-adherent. There was 84% adherence
for ritonavir and 68% for nelfinavir. Most difficulties were
found with nelfinavir, and included poor taste, patient
refusal, and scheduling problems. Adherence was found to
be direcily correlated with efficacy: full adherence (FA) was
seen in 92% of children with a decrease in viral load greater
han or equal IQ 2 log" and in 64% of children wirh smaller
man 2 log,o decrease in viral load.
Secondly, i caregivers are not well prepared for adherence
issues before starting HAART, or if regimens are too
onerous to follow, treatment is likely to fail. Every effort
should be made to see the burden of adherence from the
caregiver's point of view. Meticulous attention to detail
offers the greatest likelihood of making HAART asuccessful
venture. The key element to adherence lies in the amountof
time and care the hea/rh care worker can devote to the
effort ofexplaining rhe purpose and practice ofadherence.
Highly active antiretroviral therapy (HAARn can achieve
control of viral replication in HIV-, -infected children who
adhere to therapy, but there are two major challenges to its
successful use:
• Complex regimens which include multiple medications
and dosing inteNals, and
• Formulations that are difficult for caregivers to prepare
or are unpalatable. Such medications will be less likely
to be administered to a child.
A few points worth noting when prescribing HAART in
developing countries are, firstly, that a low-price HAART
regimen is not necessarily the cheapest option if it adds
complexity to administration (crushing, suspending and
carefully measuring volumes of water). Although the
paediatric suspensions are more expensive than other
dosage forms, i.e. tablets, powders and capsules, they
facilitate the preparation by caregivers, ease
administration, and as a result, improve adherence. In fact,
the majority of charity-funded HAART programmes have
opted for relatively expensive, but simple, suspension-
based regimens because in the long term the costs and
outcomes are better.
CHAllENGES IN PAEDIATRIC ADHERENCE
Fortunately these problems can be overcome.
Unfortunately, South African children have rarely been
enrolled as subjects in drug trials, and therefore few local
paediatricians in public or academic practice have been
able to gain experience in using HAART. Clinical experience
wirh antiretrovirals has mostly been restricred to
physicians in privare pracrice and rhose engaged in drug
rrials.
OCTOHHl 2002
ADHERENCE - RRST WORLD V. THIRD WORLD
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Fig. 1. A well-used diary card.
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As infected children require correct nutritional support and
timeous and adequate treatment of intercurrent infections,
caregivers need to be informed about both of these issues.
The necessary measures to protect against opportunistic
infections need to be explained, together with the
importance of adherence to any prophylactic medications
for opportunistic infections.
PROMOTING ADHERENCE TO HAART - SUFFICIENT
COUNSEWNG AND SUPPORT
Caregivers need to understand the critical importance of
continuity of care. Clinics must run on a 'no wrong days'
basis, and caregivers should also have access to a 24-hour
emergency/help line for information and support
In a sophisticated First-World trial, Reddington et aI'
reported on their interview of 90 children's parents that:
• 170,0 had missed a dose in the previous 24 hours
• 43% had missed at least 1 dose in the previous week.
• non-adherent caregivers tended to consider adherence
impossible, needed more practical help with
Only when physicians are sure that all of the above are in
place should HMRT be considered. Then and only then
should HMRT be commenced.
• fear and lack of belief in medications
• Iow self-esteem
• unstructured chaotic life
• lack of family support.
It is obvious from what we know that parents/caregivers
require detailed, in-depth and ongoing counselling in order
to provide comprehensive care to children receiving HMRT.
Medical staff require sufficient time to explain:
• child-proof tops on medicine bottles
• 'colour-coding' of medicines
• the importance of keeping accurate 'diary cards' of
administration of doses of medication (Fig. 1), and
• the critical importance of adherence.
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HIVATIS' website lists reasons why children fail to comply
with treatment and barriers to adherence:
WHAT WE THINK WE KNOW - AN ANALYSIS OF
CONSENSUS
In another paediatric study' two characteristics of
caregivers were identified as associated with non-
adherence. One was inability to describe the medication,
and the other was non-attendance at appointments. This
study confirmed that adherence of 90% or higher is
associated with a virological response.
Caregivers of children enrolled in clinical trials are often
more thoroughly counselled and supported than in
ordinary clinical practice. This has been found to impact on
efficacy and adherence to HMRl' Over the first 180 days
it was found that even among clinical trial subjects only
58% were totally compliant, and a non-detectable viral
load was recorded in only 52% of patients. Only 3 patients
(100/0) maintained a viral load < 400 copies/m!. The trial
confirmed that there is a high risk of treatment failure
unless there is adherence.
In another, smaller adherence trial' in 2001, 44 children
with a mean age of 9.4 years were studied. There was a
mean burden of 8.1 pills or syrup doses, and 54.5% of
children also required food restrictions. Mothers
administered the medication in 58% of cases. It was
shown that 20 - 30% had missed at least 1 dose in 3 days.
The main problems cited were:
• too many pills, too many doses
• difficulty swallowing pills
• taking medication at school, and when away from
home
• refusal to take medication and spitting up medication,
and
• food interactions.
The results highlighted the need for improved formulations
and better counselling tailored to meet individual
treatment.




• problems around meals
• non-disclosure to others
• hiding/re-labelling medicines
• defaults at clinic
• midday doses.
Barriers to adherence:
• denial and fear
• misinformation
• distrust
administration, and were less likely to have told
school/day care about treatment
Interventions thought to be helpful included:
• better tasting medicines (81%)
• longer dosing intervals (72%)
• medications not requiring refrigeration (63%)
• telephone advice (62%)
• follow-up call (52010)
• pill organiser (56010).
It is assumed by many health care professionals that
adherence is not good in developing populations, but South
African triallists Orrell et al.' have asserted that this is not
true in a clinical trial setting. Strategies that will improve
adherence include:
• education regarding the disease and HAART
• preparatory visits to the clinic
• cues, reminders
• social and community support
• time from health care workers.
Adherence is improved by commonsense medication:
• simple regimens - twice daily, no mixing [suspensions
under age 3)
• palatable medications
• no need for refrigeration
• 'Adaptacaps:
Drug manufacturers could assist by expanding the use of
the 'Adaptacap', which currently only comes with
nevirapine. The device facilitates drawing up of medicine
into a syringe for administration. (Fortunately it also
happens to fit onto a lamivudine top.) There is a
commercially available universal adapter made by Apex.
AIDING ADHERENCE
In asmall group of poor responders, Gigliotti et al." studied
the impact of directly observed therapy (DOn on viral load
and found that it was highly effective.
In one study," gastrostomy tubes were inserted into 17
patients with poor compliance. This did result in a decrease
in viral load, but the biggest drop was seen in those in
whom the HAART schedule was changed at the time of
insertion. Additionally, the procedure reduced the
administration time for drugs to less than 5 minutes. It
would appear to be a less practical means of improving
adherence but an interesting approach.
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WHAT WE MIGHT BE ABLE TO RESEARCH - A UST
OF ASSUMPTIONS WORTH TESTING
Certain assumptions that treaters currently hold but that
have not been tested include:
• promotion of demand rather than adherence
• encouragement of maternal self-esteem
• arrangement of cohort bookings to promote alliances
between mothers
• organisation of a buddy system for 'reciprocal DOTS'
• reward for good performance
• pride in access, therapeutic programmes, and national
success.
These may well be worth testing.
SUMMARY
• Non-adherence is common everywhere, but adherence
is entirely possible in our setting.
• Commonsense interventions promote adherence.
• Not all manufacturers are prioritising adherence.
• Families need support to achieve adherence.
• Adherence requires commitment from health care
workers.
• Health care workers need time to train caregivers.
• Extraordinary measures are sometimes indicated.
We must commit resources and innovative thought to local
adherence programmes.
I. PaMiatric: European Networi for Tr~atment of AIDS. Pat~ts' attirud~ to thrir HIV-
inkctro children being enrod~ into c placebo-ronuolltd trial: The PENTA 1 trial
PGediaO'ic European Network for Treatment of AIDS. HNM~ 1999; 1: 25-31.
1 Elored U Wu AW, Cha"sson RE, Moore RD. Adh~ence to antireuoviral and ...
prophylaxis in HIV disease. JAcquir Immune Defic Syndr Hum Rerroviro/l998; 18:
117-125.
3. Van Dyke RB, let S, Johnson GM, eral. Reported adherence as a determinant of
response to highly active ancire-traviral therapy in children who have human
immunodeficiency virus infe<:tion. fhJiarrics2002; 109: e61.
4. Pontali E, ~asi M, Toscanini F, er aL Adherence to combination antiretroviral
treatmef1t in children. HNOin Triols2001; 2: 466-473.
5. K<itko E, Johnson GM. Fowler 51.., Turner Ra ~ent of adherence with
medications in human immunodeficiency virus-infected children. flediorr Infecr{}is
)2001;20: 1174.
6. WatsOn DC. Farley lJ. Efficacy of and adherence to highly active antiretroviral
therapy In children in"etted with human immunodeficiency virus type 1. Fbfuu
InfecrDisJ 1999; 18: 682-689.
7. HIVATIS.ORG websirt.
8. Redding:on C. Cohen J. Ba 0; 10 A, et oL Adherence to medication regirntr:s amorg
ctUldml with human immunooeficiercy virus infection. flediotr Infeet Dis J 2OlJ;
19: 1148-1153.
9. Orrell C. Bekker LG and Wooa R. Adherence to antiretroviral tnerdpy - <ich~b.t
in the South African cor:text? SAt, MrdJ 2OCO; 91: 4-83-484.
10. Gigliotti F, Murante BI.., Weinberg GA. Short course dirtetly observed therapy to
monitor compliance with anrireuoviral tnerapy in human Immunodeficiency virus-
infei:teO children. Pedicu Infecr DisJ 2001; 20: 716-ns.
11. 5hingadia D, Viani RM. Y09ev R, era/. Gastrostomy tube insertion for improvemenr
of adherence to highly active antiretroviral therapy in paediatric patients with
human immunodeficiency virus. f!ediG!'ics 2000; 105: ESQ.
THf SOUTHtRN AFRICAN JOURNAL OF HIV MfOICINf
